Added to YB: 2025-05-05
Pitch date: 2025-05-02
LLY [neutral]
Eli Lilly and Company
+26.49%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
Market Cap
$893.2B
Pitch Price
$812.35
Price Target
N/A
Dividend
0.60%
EV/EBITDA
31.99
P/E
48.80
EV/Sales
15.58
Sector
Pharmaceuticals
Category
growth
Eli Lilly ($LLY): Robust growth fueled by the Obesity Therapeutics revolution
LLY (earnings update): Q1'25 revenues +45% YoY to $12.7B, EPS +29% to $3.34. Zepbound/Mounjaro driving growth with 60% obesity TRx share, 74% NRx. Orforglipron oral GLP-1 shows promising Phase 3 results with 7.9% weight loss. Guidance $58-61B FY25 revenue. Risk: formulary decisions, competition from Novo. Expect duopolistic obesity market leadership.
Read full article (3 min)